• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients - The Lancet

Mary Wilson

New member
Published:February 18, 2021
DOI:https://doi.org/10.1016/S0140-6736(21)00448-7

Sharon Amit, Gili Regev-Yochay, Arnon Afek, Yitshak Kreiss, Eyal Leshem

In December, 2020, the Israeli Government approved the BNT162b2 COVID-19 vaccine and initiated a national immunisation campaign prioritising health-care workers (HCWs), as in other countries.
[SUP]1[/SUP] This campaign coincided with a third wave of COVID-19, peaking at 10 116 daily new cases by mid-January, 2021. The Sheba Medical Centre, Israel's largest hospital with 9647 HCWs, began staff vaccination on Dec 19, 2020. All HCWs, excluding those with previous SARS-CoV-2 infection, were eligible for vaccination. Clinical trial data of BNT162b2 vaccine estimated an early vaccine efficacy in preventing COVID-19 of 52?4% before dose two, and 90.5% on days 2–7 after dose two.
[SUP]2[/SUP] A recent analysis of BNT162b2 vaccine data estimated vaccine efficacy of 89–91% during days 15–28 after the first dose.
[SUP]3[/SUP] We examined early reductions in SARS-CoV-2 infection and COVID-19 rates in vaccinated HCWs. ...

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00448-7/fulltext
 
Back
Top Bottom